[Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects].
Fibrous dysplasia covers a variety of rather different clinical pictures. Its therapy therefore has to be individually adapted. In addition to the orthopaedic surgeon, endocrinologists and craniofacial surgeons are also involved in the process. In the present contribution the role of modern bisphosphonates as a conservative treatment strategy is discussed with regard to the prevalent therapeutic possibilities. The literature as well as personal experience show them to be an especially valid option for the treatment of polyostotic fibrous dysplasia and the various syndromes.
Egner-Höbarth
Sigrun
S
Universitätsklinik für Orthopädie, Auenbruggerplatz 5-7, A-8036 Graz. sigrun.egner@meduni-graz.at
Welkerling
H
H
Windhager
R
R
D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005357:Fibrous Dysplasia of Bone / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D004164:Diphosphonates